Dossier assessment
Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Patients with achondroplasia 2 years of age and older whose epiphyses are not closed
Indication of non-quantifiable added benefit
Press releases
Vosoritide for achondroplasia: indication of added benefit for children aged two years and older
Additional information
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.
Project details
- Project no.
- A23-92
- Commission
- Commission awarded on 01.09.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-92
Connected Projects
-
Dossier assessment
Vosoritide (achondroplasia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Addendum
Vosoritide (achondroplasia, ≥ 2 years) – Addendum to Project A23-92
Status: Commission completed
-
Dossier assessment
Vosoritide (achondroplasia, ≥ 4 months) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed